Risk factors for recurrence of external genital endometriosis after surgical treatment: prospective cohortant study
This prospective cohort study found that intensive acyclic pelvic pain, prior surgeries, infertility, and advanced disease stages are predictive factors for EGE recurrence after surgery, while dienogest or goserelin hormonal therapy effectively prevents recurrence.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This prospective cohort study enrolled 100 patients with external genital endometriosis who underwent laparoscopic surgery between 2014 and 2016; the diagnosis was confirmed histologically and blood samples were collected before and after surgery using direct mass spectrometry to assess recurrence. Recurrence was diagnosed in 22% of participants within 18–36 months, with higher recurrence in those who did not receive postoperative hormonal therapy; dienogest 2 mg for 6–9 months or goserelin 3.6 mg for 3–6 months showed the greatest effectiveness, whereas combined oral contraceptives did not reduce recurrence (not recommended for recurrence prevention). Clinically, increased recurrence probability was associated with intense acyclic pelvic pain, prior endometriosis surgery, infertility, ovulation stimulation during ART/IVF, more advanced disease (III–IV), severe pelvic adhesions, infiltrative forms, larger endometriotic cysts, and bilateral ovarian involvement. The paper also reports a lipid panel in plasma enabling early noninvasive detection of recurrence by mass spectrometry (sensitivity 93%, specificity 95%), and notes that recurrence analysis relied on the study’s enrolled cohort and follow-up window. This paper is centrally about endometriosis — it focuses specifically on risk factors and postoperative recurrence prevention/diagnosis for external genital endometriosis.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
7,649 characters
· extracted from
oa-html
· click to expand
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (10)
- Clinical, Anamnestic and Diagnostic Features of Patients with Different Stages and Localization of Endometriosis 2025
- Personalization of the relapse probability and prevention of post-surgery ovarian endometriosis 2025
- The problem of recurrence of ovarian endometriomas 2025
- Clinical and history features of patients with recurrent deep endometriosis: A retrospective study 2024
- Features of the expression of sex steroid hormone receptors in first detected and recurrent external genital endometriosis 2022
- THE INFORMATIVE VALUE OF PELVIC ULTRASONOGRAPHY IN RECURRENT EXTERNAL GENITAL ENDOMETRIOSIS 2021
- Clinical and diagnostic aspects of deep infiltrative endometriosis (diagnosis, treatment, recurrence) 2021
- Study of dienogest clinical efficacy in the treatment of adenomyosis 2021
- Hormone therapy for patients with endometriosis: status update on the problem (literature review) 2020
- WAYS OF IMPROVING TREATMENT OF WOMAN OF REPRODUCTIVE AGE WITH ENDOMETRIAL OVARIAN CYSTS (literature review) 2019
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00